Related Experiment Video
Updated: Apr 17, 2026

Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula
Published on: January 26, 2024
Kidney cancer, version 3.2015
Robert J Motzer1, Eric Jonasch1, Neeraj Agarwal1
1From Memorial Sloan Kettering Cancer Center; The University of Texas MD Anderson Cancer Center; Huntsman Cancer Institute at the University of Utah; Dana-Farber/Brigham and Women's Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; University of Alabama at Birmingham Comprehensive Cancer Center; Vanderbilt-Ingram Cancer Center; Mayo Clinic Cancer Center; UC San Diego Moores Cancer Center; Moffitt Cancer Center; Stanford Cancer Institute; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; University of Colorado Cancer Center; City of Hope Comprehensive Cancer Center; Roswell Park Cancer Institute;University of Washington/Seattle Cancer Care Alliance; Massachusetts General Hospital Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Fox Chase Cancer Center; Duke Cancer Institute; University of Michigan Comprehensive Cancer Center; UCSF Helen Diller Family Comprehensive Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; and National Comprehensive Cancer Network.
Abstract:
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal carcinoma. These NCCN Guidelines Insights highlight the recent updates/changes in these guidelines, and updates include axitinib as first-line treatment option for patients with clear cell renal carcinoma, new data to support pazopanib as subsequent therapy for patients with clear cell carcinoma after first-line treatment with another tyrosine kinase inhibitor, and guidelines for follow-up of patients with renal cell carcinoma.
Insights
The NCCN Kidney Cancer Guidelines now include axitinib as a first-line treatment for clear cell renal carcinoma. Updates also cover pazopanib for subsequent therapy and follow-up care for renal cell carcinoma patients.
Area of Science:
- Oncology
- Clinical Practice Guidelines
Background:
- The National Comprehensive Cancer Network (NCCN) provides evidence-based guidelines for cancer treatment.
- Kidney cancer management involves distinct approaches for clear cell and non-clear cell renal carcinoma.
Purpose of the Study:
- To summarize recent updates to the NCCN Guidelines for Kidney Cancer.
- To highlight changes in treatment recommendations and follow-up care.
Main Methods:
- Review of updated NCCN Guidelines for Kidney Cancer.
- Analysis of new data supporting treatment recommendations.
Main Results:
- Axitinib is now recommended as a first-line treatment option for clear cell renal carcinoma.
- Pazopanib is supported by new data for subsequent therapy in clear cell carcinoma after first-line tyrosine kinase inhibitor treatment.
- Updated guidelines for the follow-up of renal cell carcinoma patients are included.
Conclusions:
- The NCCN Guidelines for Kidney Cancer have been updated to reflect the latest evidence.
- These updates provide clinicians with current recommendations for managing renal cell carcinoma.
Related Concept Videos
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer
Cancer
Mechanisms of Retrovirus-induced Cancers
Mechanisms of Retrovirus-induced Cancers
Cancer Prevention
Some...

